Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.
Rachel A. Freedman, MD, MPH
Advertisement
Articles by Rachel A. Freedman, MD, MPH
Advertisement
Latest Updated Articles
Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain MetastasesPublished: July 5th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
